dilazep has been researched along with Anemia in 1 studies
Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Hosoya, T | 1 |
1 other study available for dilazep and Anemia
| Article | Year |
|---|---|
Antiplatelet therapy decreases the incidence of erythropoietin-induced hypertension in predialysis patients.
Topics: Adult; Aged; Anemia; Dilazep; Dipyridamole; Erythropoietin; Female; Hematocrit; Humans; Hypertension | 1999 |